Skip to main content

Table 1 Characteristics of included studies

From: Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis

Study

Region

Study Period

No. of patients

Follow-up (months)

Age (years)

Gender (male/female)

Tumor histology

Type of PS scale

Survival

NOS

ccRCC

non-ccRCC

Unknown

Bamias 2010

UK

2006–2009

109

15.8 (0.1–31.5)

59 (30–79)

80/29

100

7

2

ECOG PS

OS

7

You 2011

Korea

2006–2009

78

10

59 (34–79)

57/21

78

–

–

KPS

OS, PFS

8

Steffens 2011

Germany

2005–2010

116

21 (9.5–30.3)

61 ± 11.1

79/37

98

18

–

ECOG PS

OS, PFS

7

Abel 2011

USA

2004–2009

75

15 (10.5–23.0)

60.0 (23–80)

54/21

55

11

9

ECOG PS

OS

8

Seidel 2012

Germany

2005–2011

119

NA

61 (27–72)

84/35

106

13

–

ECOG PS

OS

6

Powles 2014

UK

2006–2009

98

NA

59 (37–78)

75/23

98

–

–

ECOG PS

OS

8

Poprach 2014

Czech

2007–2012

319

15

62 (45–77)

221/98

309

NA

NA

ECOG PS

OS, PFS

7

Park 2014

Korea

2006–2011

83

18 (1–62)

57 (33–80)

60/23

83

–

–

KPS

OS, PFS

7

Kust 2014

Croatia

2008–2013

41

40 (5–48)

60

34/7

41

–

–

ECOG PS

OS, PFS

6

Gore 2015

USA

2005–2007

4543

13.6 (1–71.3)

59 (19–89)

3364/1179

4010

532

1

ECOG PS

OS

8

Shin 2015

Korea

2006–2011

182

34.6 (2.3–171.7)

56.9 (33–85)

132/50

182

–

–

KPS

OS, PFS

6

Wang 2016

China

2006–2015

282

37

58 (19–83)

200/82

233

49

–

KPS

OS

8

Rausch 2016

Germany

2003–2014

88

34.6 (26.4–42.2)

68.8 (30.8–81.5)

69/19

81

6

6

ECOG PS

OS

6

Chrom 2016

Poland

2010–2014

266

46.1 (41.2–51.0)

61 (22–85)

180/86

248

18

–

ECOG PS

OS

6

Artac 2016

Turkey

1998–2012

104

20.8 (1.8–55.5)

57 (29–88)

77/27

65

15

24

KPS

PFS

8

Furukawa 2016

Japan

2009–2011

39

15.1

61 (36–77)

27/12

39

–

–

KPS

PFS

7

Hwang 2017

Korea

2007–2013

56

20.2 (1.5–78.3)

60 (37–88)

44/12

51

5

–

KPS

OS

7

Teishima 2017

Japan

2007–2016

118

NA

64 (40–84)

97/21

102

16

–

ECOG PS

OS

7

Zucca 2018

Brazil

2008–2014

64

18.5

57 (30–81)

42/22

51

13

–

KPS

OS

7

  1. ccRCC clear cell renal cell carcinoma, PS performance status, NOS Newcastle-Ottawa score, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NA not available